Compare prices and buy GHRP-6 from 9 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (C46H56N12O6, CAS 87616-84-0), reported by Cyril Bowers' laboratory after earlier work on analogs of the opioid peptide Met-enkephalin. It is an agonist at the ghrelin receptor, GHS-R1a, and released growth hormone in healthy men, and a study in patients whose hypothalamus was disconnected from the pituitary pointed to the hypothalamus as its main site of action. GHRP-2 and hexarelin were developed from it. In rats and goldfish it stimulated eating, while the controlled human food-intake studies in this class used GHRP-2. It is not FDA-approved, and FDA lists it in Category 2 of its 503B compounding policy.
For research purposes only. Not medical advice.
GHRP-6 is a synthetic hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, with the formula C46H56N12O6 and CAS 87616-84-0. Two of its six residues, the tryptophan at position 2 and the phenylalanine at position 5, are D-amino acids, the mirror-image forms.
Cyril Bowers' laboratory at Tulane reported it in 1984 (Bowers, Endocrinology, 1984), at the end of a design line that began with analogs of the opioid peptide Met-enkephalin. The GHRP-2 page covers that history and the later discovery of the receptor and of ghrelin. Both GHRP-2 and hexarelin were built on GHRP-6. GHRP-2 keeps its last four residues, and hexarelin adds a methyl group to its D-tryptophan.
GHRP-6 is an agonist at the ghrelin receptor, GHS-R1a, the target it shares with GHRP-2, hexarelin and ipamorelin. Sermorelin, tesamorelin and CJC-1295 No DAC act at a different receptor, the GHRH receptor.
The class's most cited human result used GHRP-6. In 18 healthy men, GHRP-6 given together with GHRH released growth hormone synergistically, and the authors took that as a sign the two act independently (Bowers, Journal of Clinical Endocrinology and Metabolism, 1990). A 1995 study in patients whose hypothalamus was disconnected from the pituitary, described below, pointed to the hypothalamus as GHRP-6's main site of action.
Its effects reach beyond growth hormone. In a 1998 swine study, GHRP-6 and GHRP-2 raised ACTH and cortisol while ipamorelin did not (Raun, European Journal of Endocrinology).
The appetite evidence for GHRP-6 itself comes from animals.
A Europe PMC search in October 2026 found no controlled food-intake study of GHRP-6 in people.
ClinicalTrials.gov holds no registration under GHRP-6, SK&F 110679 or growth hormone releasing hexapeptide as of October 2026.
No US application for GHRP-6 appears in drugsfda as of October 2026. SmithKline Beecham received an orphan drug designation for it in 1990, for long-term treatment of children with growth failure due to inadequate growth hormone secretion. FDA's orphan database lists that designation as withdrawn or revoked, and no product was approved for the use. Its compounding status depends on pathway:
FDA cites possible immunogenicity for certain routes and, from what it calls limited safety information, a potential effect on cortisol and a rise in blood glucose from reduced insulin sensitivity. GHRP-2's Category 2 entry covers only injectable and nasal use, so the two siblings differ there. GHRP-6 is absent from the Category 2 page's withdrawn-nominations table and from every Pharmacy Compounding Advisory Committee agenda posted since 2016. The sermorelin page covers the nomination of a fixed sermorelin, GHRP-2 and GHRP-6 vial.
The direct evidence is from animals. In sated rats, GHRP-6 injected into the brain made eating more likely as the dose rose, without a matching change in blood growth hormone (Locke, Life Sciences, 1995), and in goldfish it stimulated food intake much as ghrelin does (Yahashi, Peptides, 2012). The controlled human food-intake studies in this class used its sibling GHRP-2 (Laferrere, Journal of Clinical Endocrinology and Metabolism, 2005, and Obesity, 2006). A Europe PMC search in October 2026 found no controlled food-intake study of GHRP-6 itself in people.
The human studies differ. In a 1989 study of 17 healthy men, growth hormone rose while LH, FSH, TSH and ACTH did not change (Ilson, Journal of Clinical Endocrinology and Metabolism, 1989). In 18 healthy men, prolactin and cortisol rose about twofold, but only at the highest dose tested (Bowers, same journal, 1990). In a 1998 swine study, GHRP-6 and GHRP-2 both raised ACTH and cortisol while ipamorelin did not. FDA's Category 2 entry for GHRP-6 names a potential effect on cortisol among its safety concerns.
Under section 503B, which covers outsourcing facilities, FDA placed GHRP-6 in Category 2, its list of bulk drug substances that raise significant safety risks, on September 29, 2023. The entry carries no route restriction, unlike GHRP-2's, which covers injectable and nasal use only. FDA cited possible immunogenicity for certain routes and, from limited safety information, a potential effect on cortisol and a rise in blood glucose from reduced insulin sensitivity. Under section 503A, GHRP-6 is in Category 3, nominated without adequate support. As of October 2026 it is not in the withdrawn-nominations table, and no Pharmacy Compounding Advisory Committee agenda posted since 2016 has named it.
It was studied under the SmithKline code SK&F 110679. An early human study, in 17 healthy men, appeared in 1989 (Ilson, Journal of Clinical Endocrinology and Metabolism), and SmithKline Beecham received a US orphan drug designation in 1990 for long-term treatment of children with growth failure due to inadequate growth hormone secretion. FDA's orphan database lists that designation as withdrawn or revoked, and no product was approved. As of October 2026, drugsfda holds no application for GHRP-6, and ClinicalTrials.gov holds no registration under GHRP-6 or SK&F 110679.
GHRP-6 is sold by 9 research peptide vendors indexed on PeptideScouter, with 13 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
7 of the 9 indexed vendors currently have GHRP-6 in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Iron Protocol currently lists GHRP-6 at $2.34/mg, the lowest listed price across 9 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $1.99/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 9 vendors listing GHRP-6 publish a PeptideScouter code, worth 10% to 15% off. Applied, the lowest effective price falls from $2.34/mg listed to $1.99/mg at Iron Protocol. Each vendor's code is shown beside its price in the table above.
GHRP-6 ranges from $2.34/mg to $7.00/mg across 13 listings from 9 research peptide vendors, normalized to USD per milligram and refreshed daily.
9 research peptide vendors currently list GHRP-6 on PeptideScouter, with 7 in stock right now. We track 13 listings across size and kit variants.
GHRP-6's CAS Registry Number is 87616-84-0.
